Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death—Results from the Norwegian Prostate Cancer Consortium

Adherence to a risk‐adapted screening strategy for prostate cancer: First results of the PROBASE trial

(2022) Agne Krilaviciute et al.   INTERNATIONAL JOURNAL OF CANCER

The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate

(2021) Kimia Kohestani et al.   Scandinavian Journal of Urology

Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021

(2021) Hendrik Van Poppel et al.   EUROPEAN UROLOGY

Prespecified 4 Kallikrein Marker Model (4Kscore) at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years

(2020) Emily A. Vertosick et al.   JOURNAL OF UROLOGY

Reconsidering Prostate Cancer Mortality — The Future of PSA Screening

(2020) H. Gilbert Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men

(2018) Daniel D. Sjoberg et al.   EUROPEAN UROLOGY

A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale

(2017) Anssi Auvinen et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer

(2016) Mark A. Preston et al.   JOURNAL OF CLINICAL ONCOLOGY

Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case–Control Study

(2015) Pär Stattin et al.   EUROPEAN UROLOGY

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study

(2014) S. Carlsson et al.   BMJ-British Medical Journal

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

(2013) A. J. Vickers et al.   BMJ-British Medical Journal

The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group

(2010) A. J. Vickers et al.   CLINICAL CANCER RESEARCH